Skip to main content
Premium Trial:

Request an Annual Quote

Nanopoint, Cellexus Biosystems, BioTek Instruments, Thermo Fisher Scientific

Nanopoint this week announced the availability of its cellTRAY Imaging System CT-1000. The company said that the technology is designed for live cell experimentation and imaging at high levels of precision, and significantly reduces the cost per experiment.
Scientists can use the system to isolate cells into an array of micro-wells connected via fluidic channels. Researchers can observe individual cells throughout the experiment, automatically navigate the wells, and capture images of live cells over time.

Cellexus Biosystems this week announced the launch of the CellMaker Lite2 disposable bioreactor. The system incorporates several new features. 
For example, it can now control the flow of blended gases that are required to grow mammalian cells. In addition, the system can independently deliver gases to the aeration system in the base of the disposable cell culture bag (the CellexusBag) and to the large surface area above the cell culture.
Other features include a 60 percent smaller footprint, new control software, and several other changes to make it easier for the operator to install and start the cell culture process without the need for a service engineer or other installation specialist.

BioTek Instruments this week unveiled its new patent-pending Synergy 4 multi-detection microplate reader. According to the company, the Synergy 4 is the first multi-mode reader that combines both filter-based and quadruple monochromator-based fluorescence detection technology.
In addition, Synergy 4 includes fluorescence intensity, luminescence, fluorescence polarization, time-resolved fluorescence, and UV-visible absorbance for flexibility in microplate-based assay choice.
The manufacturer said that the combination of the filter and monochromator systems in one unit means that microplate assay choice is no longer restricted by the technology of the microplate reader.

Thermo Fisher Scientific this week introduced its NUNC 96- and 384-well optical bottom plates. The company said that the plates feature new materials and surfaces with enhanced capabilities for cell assays and drug discovery. The plates combine an upper structure bonded to a clear base that provides optical clarity in imaging applications using microscopes or plate readers.
In addition, the plates are available with upper structures in black for fluorescence studies, or white for luminescence assays. The three optically clear materials used for the plate bottoms are #1.5 borosilicate cover glass, polystyrene, or fluorocarbon.
The NUNC 384-well optical bottom plates have a redesigned skirt style to facilitate robotic handling and bar-coding functions.
The NUNC optical bottom plate with polystyrene base now has a polystyrene film that provides lower background fluorescence and fewer fluorescent artifacts. Flat, optically clear #1.5 borosilicate cover glass is bonded to the upper structure with a patented process.
The 50 µm thick fluorocarbon base, which is available on new CytoWell plates, is half the thickness of most plastic films and is also gas permeable. Exhibiting low auto-fluorescence and UV transparency, the fluorocarbon base provides increased sensitivity and facilitates the use of markers and dyes not normally applicable in polymer plates.
Surface treatments available for NUNC optical bottom plates include: non-treated, cell culture treated, Poly-D-Lysine, Collagen I, CC2, and CC3.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more